BACKGROUND: Chromosome 9p21 single nucleotide polymorphisms (SNPs) have been shown to be associated with coronary heart disease in multiple studies. The aim of the present study was to identify whether these SNPs are associated with recurrent myocardial infarction (MI), revascularization, or death in acute coronary syndrome (ACS) patients or in those undergoing coronary artery bypass grafting (CABG). METHODS AND RESULTS: TexGen registry participants with ACS (n=2,067) or CABG (n=1,176) were evaluated, to assess whether 9p21 SNPs (rs1333049, rs2383206, rs10757278, rs10757274) were associated with recurrent MI (primary outcome), recurrent revascularization, or death (secondary outcomes) at approximately 3.2 years of follow-up. Carriers of risk allele (C) for rs1333049 presented at an earlier age (62 vs. 63.5 years in non-carriers, P=0.0004) with more extensive disease (number of vessels with significant stenosis: 1.9 vs. 1.7 in non-carriers, P=0.001) in the ACS group. In adjusted models, the C allele was not associated with recurrent MI (hazard ratio [HR], 1.01; 95% confidence interval [CI]: 0.74-1.38), recurrent revascularization (HR, 0.98; 95%CI: 0.78-1.23), or death (HR, 0.91; 95%CI: 0.69-1.18) in the ACS or CABG groups (recurrent MI: HR, 0.64; 95%CI: 0.40-1.05; recurrent revascularization: HR, 0.98; 95%CI: 0.61-1.55; death: HR, 0.89; 95%CI: 0.61-1.30). Results were similar for the other 3 SNPs. CONCLUSIONS: 9p21 SNPs were not associated with recurrent MI, revascularization, or mortality after ACS or CABG. Individuals with the rs1333049 C allele, however, may present with earlier and more extensive disease.
BACKGROUND: Chromosome 9p21 single nucleotide polymorphisms (SNPs) have been shown to be associated with coronary heart disease in multiple studies. The aim of the present study was to identify whether these SNPs are associated with recurrent myocardial infarction (MI), revascularization, or death in acute coronary syndrome (ACS) patients or in those undergoing coronary artery bypass grafting (CABG). METHODS AND RESULTS: TexGen registry participants with ACS (n=2,067) or CABG (n=1,176) were evaluated, to assess whether 9p21 SNPs (rs1333049, rs2383206, rs10757278, rs10757274) were associated with recurrent MI (primary outcome), recurrent revascularization, or death (secondary outcomes) at approximately 3.2 years of follow-up. Carriers of risk allele (C) for rs1333049 presented at an earlier age (62 vs. 63.5 years in non-carriers, P=0.0004) with more extensive disease (number of vessels with significant stenosis: 1.9 vs. 1.7 in non-carriers, P=0.001) in the ACS group. In adjusted models, the C allele was not associated with recurrent MI (hazard ratio [HR], 1.01; 95% confidence interval [CI]: 0.74-1.38), recurrent revascularization (HR, 0.98; 95%CI: 0.78-1.23), or death (HR, 0.91; 95%CI: 0.69-1.18) in the ACS or CABG groups (recurrent MI: HR, 0.64; 95%CI: 0.40-1.05; recurrent revascularization: HR, 0.98; 95%CI: 0.61-1.55; death: HR, 0.89; 95%CI: 0.61-1.30). Results were similar for the other 3 SNPs. CONCLUSIONS: 9p21 SNPs were not associated with recurrent MI, revascularization, or mortality after ACS or CABG. Individuals with the rs1333049 C allele, however, may present with earlier and more extensive disease.
Authors: Ruth McPherson; Alexander Pertsemlidis; Nihan Kavaslar; Alexandre Stewart; Robert Roberts; David R Cox; David A Hinds; Len A Pennacchio; Anne Tybjaerg-Hansen; Aaron R Folsom; Eric Boerwinkle; Helen H Hobbs; Jonathan C Cohen Journal: Science Date: 2007-05-03 Impact factor: 47.728
Authors: Christopher P Cannon; Eugene Braunwald; Carolyn H McCabe; Daniel J Rader; Jean L Rouleau; Rene Belder; Steven V Joyal; Karen A Hill; Marc A Pfeffer; Allan M Skene Journal: N Engl J Med Date: 2004-03-08 Impact factor: 91.245
Authors: Heribert Schunkert; Anika Götz; Peter Braund; Ralph McGinnis; David-Alexandre Tregouet; Massimo Mangino; Patrick Linsel-Nitschke; Francois Cambien; Christian Hengstenberg; Klaus Stark; Stefan Blankenberg; Laurence Tiret; Pierre Ducimetiere; Andrew Keniry; Mohammed J R Ghori; Stefan Schreiber; Nour Eddine El Mokhtari; Alistair S Hall; Richard J Dixon; Alison H Goodall; Henrike Liptau; Helen Pollard; Daniel F Schwarz; Ludwig A Hothorn; H-Erich Wichmann; Inke R König; Marcus Fischer; Christa Meisinger; Willem Ouwehand; Panos Deloukas; John R Thompson; Jeanette Erdmann; Andreas Ziegler; Nilesh J Samani Journal: Circulation Date: 2008-03-24 Impact factor: 29.690
Authors: Jeffrey L Anderson; Benjamin D Horne; Matthew J Kolek; Joseph B Muhlestein; Chrissa P Mower; James J Park; Heidi T May; Nicola J Camp; John F Carlquist Journal: Am Heart J Date: 2008-10-11 Impact factor: 4.749
Authors: Ariel Brautbar; Christie M Ballantyne; Kim Lawson; Vijay Nambi; Lloyd Chambless; Aaron R Folsom; James T Willerson; Eric Boerwinkle Journal: Circ Cardiovasc Genet Date: 2009-04-21
Authors: Edward D Coverstone; Richard G Bach; LiShiun Chen; Laura J Bierut; Allie Y Li; Petra A Lenzini; Heidi C O'Neill; John A Spertus; Carmen C Sucharov; Jerry A Stitzel; Joel D Schilling; Sharon Cresci Journal: Basic Res Cardiol Date: 2018-08-10 Impact factor: 17.165
Authors: Jennifer Sanner; Megan L Grove; Erica Yu; F Gerard Moeller; Stanley G Cron; Eric Boerwinkle; Alanna C Morrison; Lorraine Frazier Journal: Biol Res Nurs Date: 2018-01-03 Impact factor: 2.522
Authors: Salim S Virani; Vei-Vei Lee; Ariel Brautbar; Megan L Grove; Vijay Nambi; Mahboob Alam; MacArthur Elayda; James M Wilson; James T Willerson; Eric Boerwinkle; Christie M Ballantyne Journal: Am J Cardiol Date: 2013-07-25 Impact factor: 2.778
Authors: Miklos D Kertai; Yi-Ju Li; Yen-Wei Li; Yunqi Ji; John Alexander; Mark F Newman; Peter K Smith; Diane Joseph; Joseph P Mathew; Mihai V Podgoreanu Journal: BMJ Open Date: 2015-05-06 Impact factor: 2.692
Authors: Gijs W D Landman; Jana V van Vliet-Ostaptchouk; Nanne Kleefstra; Kornelis J J van Hateren; Iefke Drion; Klaas H Groenier; Rijk O B Gans; Harold Snieder; Marten H Hofker; Henk J G Bilo Journal: Cardiovasc Diabetol Date: 2012-11-07 Impact factor: 9.951